Mediar Therapeutics Completes Enrollment in Phase 2 WISPer Trial of MTX-463 in Idiopathic Pulmonary Fibrosis (IPF)
First-in-class antibody MTX-463 targets WISP-1, a secreted matricellular protein implicated in fibrosis progression Global study rapidly enrolled 168 patients across 70+ sites spanning North and South America, Europe and Australia BOSTON, Oct. 7, 2026 /PRNewswire/ -- Mediar Therapeutics,...
Covered in this story
Call it yourself
No calls on $MTX yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Minerals Technologies Inc →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.